Oculis
Oculis is a global biopharmaceutical company developing treatments for neuro-ophthalmic and ophthalmic diseases. The company's pipeline includes Privosegtor, a small molecule candidate for optic neuritis and NAION, and Licaminlimab, an anti-TNFα eye drop for dry eye disease. These therapies target patients suffering from permanent visual impairment and ocular inflammation through neuroprotective and precision medicine approaches.
Biotechnology
Pharmaceuticals
Healthcare
Funding summary
- Total raised
- €236.9M
- Funding rounds
- 5
- Exit
- ipo
- Exit value
- €81.7M
Investors in Oculis
Investors on record for Oculis. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Oculis?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors